Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Tuesday

Kymera Therapeutics (NASDAQ:KYMRGet Rating) is set to post its quarterly earnings results before the market opens on Tuesday, May 3rd. Analysts expect Kymera Therapeutics to post earnings of ($0.67) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Kymera Therapeutics (NASDAQ:KYMRGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.30). Kymera Therapeutics had a negative net margin of 137.60% and a negative return on equity of 27.16%. The firm had revenue of $15.30 million during the quarter, compared to analyst estimates of $21.31 million. During the same period last year, the firm earned ($0.29) EPS. Kymera Therapeutics’s quarterly revenue was up 19.5% on a year-over-year basis. On average, analysts expect Kymera Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of KYMR stock opened at $34.51 on Tuesday. Kymera Therapeutics has a 12-month low of $33.45 and a 12-month high of $69.12. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -16.75 and a beta of 2.01. The firm has a fifty day moving average of $38.78 and a 200-day moving average of $48.37.

Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Kymera Therapeutics in a report on Thursday, March 10th. They issued a “neutral” rating and a $44.00 price target for the company. Zacks Investment Research raised shares of Kymera Therapeutics from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Wednesday, February 16th. Wells Fargo & Company began coverage on shares of Kymera Therapeutics in a report on Thursday, February 10th. They issued an “overweight” rating and a $62.00 price target for the company. Finally, Morgan Stanley reduced their target price on shares of Kymera Therapeutics from $68.00 to $66.00 and set an “equal weight” rating for the company in a research note on Wednesday, March 2nd. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Buy” and an average target price of $69.91.

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il purchased 34,408 shares of the business’s stock in a transaction on Monday, January 31st. The shares were purchased at an average cost of $40.70 per share, with a total value of $1,400,405.60. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bvf Partners L. P/Il purchased 95,901 shares of the business’s stock in a transaction on Thursday, January 27th. The shares were acquired at an average cost of $38.33 per share, for a total transaction of $3,675,885.33. The disclosure for this purchase can be found here. Insiders own 23.28% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its holdings in shares of Kymera Therapeutics by 48.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 267,790 shares of the company’s stock valued at $17,002,000 after purchasing an additional 87,583 shares during the period. Morgan Stanley raised its holdings in Kymera Therapeutics by 37.5% in the 3rd quarter. Morgan Stanley now owns 87,561 shares of the company’s stock valued at $5,142,000 after acquiring an additional 23,873 shares during the period. Norges Bank bought a new position in Kymera Therapeutics in the 4th quarter valued at about $3,439,000. California State Teachers Retirement System raised its holdings in Kymera Therapeutics by 3.4% in the 4th quarter. California State Teachers Retirement System now owns 42,354 shares of the company’s stock valued at $2,689,000 after acquiring an additional 1,390 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Kymera Therapeutics in the 4th quarter valued at about $2,038,000. 75.06% of the stock is currently owned by institutional investors.

Kymera Therapeutics Company Profile (Get Rating)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Further Reading

Earnings History for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.